|
시장보고서
상품코드
1985863
심장 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)Cardiac Biomarkers Market Size, Share & Trends Analysis Report By Type (Troponin, Creatine kinase - MB, Myoglobin, BNP and NT-proBNP), By Application, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
심장 바이오마커 시장 요약
세계의 심장 바이오마커 시장 규모는 2025년에 208억 1,000만 달러로 추계되며, 2033년까지 493억 1,000만 달러에 달할 것으로 예상되고 있으며, 2026-2033년에 CAGR 11.5%로 성장할 것으로 전망되고 있습니다.
이 시장은 급성관상동맥증후군, 심근경색, 심부전 등 심혈관 질환의 유병률 증가로 인해 조기 및 정확한 진단에 대한 수요가 증가하고 있습니다.
고감도 트로포닌 검사와 멀티마커 검사의 발전으로 임상적 판단과 환자 예후가 개선되었습니다. 또한 현장 검사(Point-of-Care) 검사의 이용 확대, 지원적 상환 제도, 심장 질환 위험이 높은 고령화 인구 증가는 세계 시장 확대를 지속적으로 견인하고 있습니다.
심혈관 질환은 전 세계에서 주요 사망 원인 중 하나입니다. 세계보건기구(WHO)의 2023년 조사에 따르면 심장질환으로 인한 사망자는 매년 약 1,790만 명으로 보고되고 있습니다. 고령화, 비만, 당뇨병, 고혈압으로 인해 이러한 질병의 유병률은 계속 증가하고 있으며, 그 결과 심장마비 및 심부전 위험에 처한 사람들의 수가 증가하고 있습니다. 심혈관 질환의 부담이 증가함에 따라 조기 발견, 정확한 진단 및 효과적인 환자 모니터링에 대한 요구가 매우 높아지고 있습니다. 여기서 심장 바이오마커가 중요한 역할을 합니다. 트로포닌, 크레아틴키나아제-MB(CK-MB), 미오글로빈 등의 바이오마커는 심근 손상을 감지하고 질병의 중증도를 평가하는데 필수적이며, 치료 방침을 결정하는 데 도움이 됩니다.
현장진단(POC) 심장 검사 키트에 대한 수요 증가는 심장 바이오마커 시장의 성장을 더욱 촉진할 것으로 예측됩니다. 기존에는 심혈관 질환의 진단을 위해서는 전문 장비와 훈련된 인력이 필요한 중앙 집중식 검사실 검사에 의존해 왔습니다. 이러한 기존 시스템에서는 특히 흉통이나 심근경색이 의심되는 응급실 방문과 같은 급성기에는 진단과 치료가 늦어질 수 있습니다. 심장 질환을 적시에 파악하는 것은 중재를 시작하고 환자의 생존율을 향상시키는 데 매우 중요하며, 이러한 지연은 심각한 임상적 결과를 초래할 수 있습니다. POC 심장 검사 키트는 응급실, 순환기 클리닉, 재택치료 현장 등 환자 진료 현장에서 직접 빠른 진단 결과를 얻고 적시에 판단할 수 있도록 도와줍니다. 트로포닌, 뇌 나트륨 이뇨 펩티드(BNP), 크레아틴 키나아제-MB(CK-MB)와 같은 주요 바이오마커는 현재 진료 현장에서 측정이 가능해져 임상의가 보다 신속하게 치료 방침을 결정할 수 있게 되었습니다. 예를 들어 POC cTn 검사는 보통 10분에서 20분 이내에 결과를 얻을 수 있습니다.
가용성 종양억제인자-2(sST2), 심장형 지방산 결합 단백질(H-FABP), 갈렉틴-3, 성장분화인자-15(GDF-15) 등의 새로운 바이오마커는 그 잠재적 임상적 유용성으로 인해 주목받고 있습니다. 예를 들어 2025년 8월 MDPI가 발표한 연구에 따르면 GDF-15, sST2, suPAR, H-FABP와 같은 바이오마커가 다양한 심혈관 질환에서 유망한 가능성을 보인 것으로 보고되었습니다.
이러한 새로운 바이오마커는 심혈관 생리학의 다양한 측면을 반영할 뿐만 아니라 조기 진단 및 치료 반응 모니터링을 개선할 수 있는 잠재력을 가지고 있습니다. 고감도 분석법, 나노테크놀러지 기반 센서 등의 기술 발전으로 이러한 바이오마커를 극히 낮은 농도로 검출할 수 있는 능력이 더욱 향상되어 보다 신속하고 정확한 임상적 판단이 가능해졌습니다. 또한 여러 바이오마커를 하나의 패널로 결합함으로써 임상의는 환자의 심혈관 상태를 보다 종합적으로 파악할 수 있고, 이를 통해 보다 개인화되고 정밀한 치료 접근법으로 전환할 수 있습니다. 연구가 진행되고 더 많은 증거가 밝혀짐에 따라 이러한 새로운 심장 바이오마커는 심장병 환자의 예후를 개선하는 데 중요한 역할을 할 것으로 기대됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 시장 변수, 동향, 범위
제4장 유형별 사업 분석
제5장 용도별 사업 분석
제6장 최종 용도별 사업 분석
제7장 지역별 사업 분석
제8장 경쟁 구도
KSA 26.04.23Cardiac Biomarkers Market Summary
The global cardiac biomarkers market size was estimated at USD 20.81 billion in 2025 and is expected to reach USD 49.31 billion by 2033, growing at a CAGR of 11.5% from 2026 to 2033. The market is driven by the rising prevalence of cardiovascular diseases such as acute coronary syndrome, myocardial infarction, and heart failure, increasing the demand for early and accurate diagnosis.
Advancements in high-sensitivity troponin assays and multi-marker testing have improved clinical decision-making and patient outcomes. In addition, expanding use of point-of-care testing, supportive reimbursement frameworks, and an aging population with higher cardiac risk continue to support market expansion globally.
Cardiovascular diseases are one of the major causes of death globally. According to the World Health Organization (WHO) survey in 2023, it was stated that approximately 17.9 million deaths due to cardiac disorders were reported each year. The prevalence of these conditions continues to rise due to an aging population, obesity, diabetes, and hypertension, leading to an increasing number of individuals at risk of heart attack or heart failure. The growing burden of cardiovascular diseases has created a critical need for early detection, accurate diagnosis, and effective patient monitoring. This is where cardiac biomarkers play a vital role. Biomarkers such as troponin, Creatine Kinase-MB (CK-MB), and myoglobin are essential for detecting myocardial injury and assessing disease severity and therefore help in making treatment decisions.
The rising demand for point-of-care (POC) cardiac testing kits is further expected to propel the growth in the cardiac biomarkers Market. Traditionally, the diagnosis of cardiovascular diseases relied on centralized laboratory testing, which requires specialized instruments and trained personnel. These conventional systems can delay diagnosis and treatment, particularly in acute settings such as emergency department admissions for chest pain or suspected myocardial infarction. Such delays can have serious clinical consequences, as timely identification of cardiac events is critical for initiating interventions and improving patient survival rates. POC cardiac testing kits enable quick diagnostic results for making timely decisions directly at the site of patient care, including emergency rooms, cardiology clinics, and in-home-based settings. Key biomarkers such as troponin, natriuretic peptide (BNP), and creatine kinase-MB (CK-MB) are now measurable at the point of care, allowing clinicians to make faster treatment decisions. For instance, POC cTn tests typically provide results within 10 to 20 minutes.
Emerging biomarkers, including soluble suppression of tumorigenicity-2 (sST2), heart-type fatty acid-binding protein (H-FABP), Galectin-3, and growth differentiation factor-15 (GDF-15), are gaining attention for their potential clinical utility. For instance, a study published by MDPI in August 2025 reported that the biomarkers GDF-15, sST2, suPAR, and H-FABP demonstrated promising potential across a range of cardiovascular diseases.
These novel biomarkers not only reflect different aspects of cardiovascular physiology but also offer the potential to improve early diagnosis and monitoring of treatment response. Advances in technology, including high-sensitivity assays and nanotechnology-based sensors, have further enhanced the ability to detect these biomarkers at very low concentrations, enabling faster and more accurate clinical decision-making. In addition, combining multiple biomarkers into panels allows clinicians to gain a more comprehensive understanding of a patient's cardiovascular status, moving toward more personalized and precise approaches to care. As research continues and more evidence emerges, these novel cardiac biomarkers are expected to play an important role in improving outcomes for patients with heart disease.
Global Cardiac Biomarkers Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021-2033. For this report, Grand View Research has segmented the cardiac biomarkers market based on type, application, end use, and region.
- Type Outlook (Revenue, USD Million, 2021 - 2033)
- Troponin
- CK-MB
- Myoglobin
- BNP and NT-proBNP
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Acute Coronary Syndrome
- Myocardial Infarction
- Congestive Heart Failure
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Laboratory Testing
- Point of Care Testing
- Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Market Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Type and Product Snapshot
- 2.3. Application and End Use Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.1.1. Increasing prevalence of cardiovascular diseases
- 3.3.1.2. Rising demand for point of care (POC) cardiac testing kits
- 3.3.1.3. Increasing focus on innovation and development of novel cardiac biomarkers
- 3.3.2. Market Restraint Analysis
- 3.3.2.1. Stringent regulatory barriers
- 3.3.2.2. Lack of specificity in cardiac biomarkers
- 3.3.1. Market Driver Analysis
- 3.4. Business Environment Analysis
- 3.4.1. PESTLE Analysis
- 3.4.2. Porter's Five Forces Analysis
- 3.5. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
- 4.1. Cardiac Biomarkers Market: Type Movement Analysis, 2025 & 2033
- 4.2. Troponin
- 4.2.1. Troponin market, 2021 - 2033 (USD Million)
- 4.3. CK-MB
- 4.3.1. CK-MB market, 2021 - 2033 (USD Million)
- 4.4. Myoglobin
- 4.4.1. Myoglobin market, 2021 - 2033 (USD Million)
- 4.5. BNP and NT-proBNP
- 4.5.1. BNP and NT-proBNP market, 2021 - 2033 (USD Million)
- 4.6. Others
- 4.6.1. Others market, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. Cardiac Biomarkers Market: Application Movement Analysis, 2025 & 2033
- 5.2. Acute Coronary Syndrome
- 5.2.1. Acute coronary syndrome market, 2021 - 2033 (USD Million)
- 5.3. Myocardial Infarction
- 5.3.1. Myocardial infarction market, 2021 - 2033 (USD Million)
- 5.4. Congestive Heart Failure
- 5.4.1. Congestive heart failure market, 2021 - 2033 (USD Million)
- 5.5. Others
- 5.5.1. Others market, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis
- 6.1. Cardiac Biomarkers Market: End Use Movement Analysis, 2025 & 2033
- 6.2. Lab Testing
- 6.2.1. Lab testing Market, 2021 - 2033 (USD Million)
- 6.3. POC testing
- 6.3.1. POC testing Market, 2021 - 2033 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Regional Market Snapshot
- 7.2. North America
- 7.2.1. North America Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.2.2.2. Key Country Dynamics
- 7.2.2.3. Regulatory Framework
- 7.2.2.4. Competitive Scenario
- 7.2.3. Canada
- 7.2.3.1. Canada Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.2.3.2. Key Country Dynamics
- 7.2.3.3. Regulatory Framework
- 7.2.3.4. Competitive Scenario
- 7.2.4. Mexico
- 7.2.4.1. Mexico Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.2.4.2. Key Country Dynamics
- 7.2.4.3. Regulatory Framework
- 7.2.4.4. Competitive Scenario
- 7.3. Europe
- 7.3.1. Europe Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.2. Germany
- 7.3.2.1. Germany Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.2.2. Key Country Dynamics
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. Competitive Scenario
- 7.3.3. UK
- 7.3.3.1. UK Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.3.2. Key Country Dynamics
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. Competitive Scenario
- 7.3.4. France
- 7.3.4.1. France Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.4.2. Key Country Dynamics
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. Competitive Scenario
- 7.3.5. Italy
- 7.3.5.1. Italy Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.5.2. Key Country Dynamics
- 7.3.5.3. Regulatory Framework
- 7.3.5.4. Competitive Scenario
- 7.3.6. Spain
- 7.3.6.1. Spain Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.6.2. Key Country Dynamics
- 7.3.6.3. Regulatory Framework
- 7.3.6.4. Competitive Scenario
- 7.3.7. Denmark
- 7.3.7.1. Denmark Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.7.2. Key Country Dynamics
- 7.3.7.3. Regulatory Framework
- 7.3.7.4. Competitive Scenario
- 7.3.8. Sweden
- 7.3.8.1. Sweden Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.8.2. Key Country Dynamics
- 7.3.8.3. Regulatory Framework
- 7.3.8.4. Competitive Scenario
- 7.3.9. Norway
- 7.3.9.1. Norway Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.3.9.2. Key Country Dynamics
- 7.3.9.3. Regulatory Framework
- 7.3.9.4. Competitive Scenario
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Japan Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.2.2. Key Country Dynamics
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Competitive Scenario
- 7.4.3. China
- 7.4.3.1. China Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.3.2. Key Country Dynamics
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Competitive Scenario
- 7.4.4. India
- 7.4.4.1. India Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.4.2. Key Country Dynamics
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Competitive Scenario
- 7.4.5. South Korea
- 7.4.5.1. South Korea Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.5.2. Key Country Dynamics
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. Competitive Scenario
- 7.4.6. Australia
- 7.4.6.1. Australia Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.6.2. Key Country Dynamics
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Competitive Scenario
- 7.4.7. Thailand
- 7.4.7.1. Thailand Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.4.7.2. Key Country Dynamics
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. Competitive Scenario
- 7.5. Latin America
- 7.5.1. Latin America Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.5.2. Key Country Dynamics
- 7.5.3. Regulatory Framework
- 7.5.4. Competitive Scenario
- 7.5.5. Brazil
- 7.5.5.1. Brazil Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.5.5.2. Key Country Dynamics
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Competitive Scenario
- 7.5.6. Argentina
- 7.5.6.1. Argentina Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.5.6.2. Key Country Dynamics
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Competitive Scenario
- 7.6. MEA
- 7.6.1. MEA Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. South Africa Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.6.2.2. Key Country Dynamics
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Competitive Scenario
- 7.6.3. Saudi Arabia
- 7.6.3.1. Saudi Arabia Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.6.3.2. Key Country Dynamics
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Competitive Scenario
- 7.6.4. UAE
- 7.6.4.1. UAE Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.6.4.2. Key Country Dynamics
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Competitive Scenario
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Cardiac Biomarkers Market, 2021 - 2033 (USD Million)
- 7.6.5.2. Key Country Dynamics
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Competitive Scenario
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.2.1. Acquisition
- 8.2.2. Collaborations
- 8.2.3. New Platform Launches
- 8.2.4. Others
- 8.3. Company Profiles/Listing
- 8.3.1. Abbott
- 8.3.1.1. Company Overview
- 8.3.1.2. Financial Performance
- 8.3.1.3. Product Benchmarking
- 8.3.1.4. Strategic Initiatives
- 8.3.2. Quidel Corporation
- 8.3.2.1. Company Overview
- 8.3.2.2. Financial Performance
- 8.3.2.3. Product Benchmarking
- 8.3.2.4. Strategic Initiatives
- 8.3.3. Siemens Healthineers
- 8.3.3.1. Company Overview
- 8.3.3.2. Financial Performance
- 8.3.3.3. Product Benchmarking
- 8.3.3.4. Strategic Initiatives
- 8.3.4. Danaher
- 8.3.4.1. Company Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Product Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. F. Hoffmann-La Roche Ltd
- 8.3.5.1. Company Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Product Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. bioMerieux SA
- 8.3.6.1. Company Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Product Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. Bio-Rad Laboratories, Inc.
- 8.3.7.1. Company Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Product Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. Randox Laboratories Ltd
- 8.3.8.1. Company Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Product Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.3.9. Creative Diagnostics
- 8.3.9.1. Company Overview
- 8.3.9.2. Financial Performance
- 8.3.9.3. Product Benchmarking
- 8.3.9.4. Strategic Initiatives
- 8.3.10. Life Diagnostics
- 8.3.10.1. Company Overview
- 8.3.10.2. Financial Performance
- 8.3.10.3. Product Benchmarking
- 8.3.10.4. Strategic Initiatives
- 8.3.1. Abbott
